Challenges and strategies to combat resistance mechanisms in thyroid cancer therapeutics - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36924302/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: Progression-free survival is curtailed by developing acquired resistance. To minimise this therapeutic liability, clinicians must be anticipatory in identifying the drivers and characterising mechanisms of on target resistance.
Pediatric thyroid surgery: Retrospective analysis on the first 25 pediatric thyroidectomies performed in a reference center for adult thyroid diseases
Source : https://www.frontiersin.org/articles/10.3389/fendo.2023.1126436/full
IntroductionPediatric thyroid carcinoma represents about 4-5% of all pediatric carcinoma with an incidence of 0.5 cases/100,000, compared to 2-10/100000 cases in the adult population. The aim of this study is...
Conclusions: Pediatric thyroid nodules are rare and distinguished from adult thyroid disease by a worse prognosis and higher malignancy rates. Our work reports a much higher malignancy rate among indeterminate TIR 3B lesions than observed in the adult population and the three patients who underwent prophylactic total thyroidectomy for activating RET gene mutation had all a definitive histological diagnosis of medullary carcinoma. Post-surgical hypoparathyroidism is a common finding in these patients: in most cases the condition is transient and it benefits from supportive therapy ...
Diffuse sclerosing variant papillary thyroid carcinoma has worse survival than classic papillary thyroid carcinoma: a meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36952650/
Diffuse sclerosing variant of papillary thyroid carcinoma (DSV) is a rare form of thyroid cancer that demonstrates more aggressive histopathology than classical papillary thyroid cancer (c-PTC) however if this leads...
Conclusions/Relevance: The high prevalence of RET fusions offers the potential to improve outcomes for patients with DSV.
Multi-omics profiling of papillary thyroid microcarcinoma reveals different somatic mutations and a unique transcriptomic signature - Journal of Translational Medicine
Source : https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-023-04045-2
Background Papillary thyroid microcarcinoma (PTMC) incidence has significantly increased, and some cases still exhibit invasive traits. The entire molecular landscape of PTMC, which can offer hints for the etiology of...
Conclusions: Our findings comprehensively define the clinical and molecular features of PTMC and may inspire new therapeutic hypotheses.
A Familial Case of Multiple Endocrine Neoplasia 2A: From Morphology to Genetic Alterations Penetration in Three Generations of a Family - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36900098/
This paper illustrates a rare syndrome of multiple endocrine neoplasia type 2A (MEN2A) in a family of three generations. In our case, the father, son and one daughter developed phaeochromocytoma...
Conclusions/Relevance: A few lessons can be learned from this unique case. Successful diagnosis requires high suspicion and surveillance and a tri-level methodology including a careful review of family history, pathology and genetic counselling.
Challenges and strategies to combat resistance mechanisms in thyroid cancer therapeutics - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36924302/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: Progression-free survival is curtailed by developing acquired resistance. To minimise this therapeutic liability, clinicians must be anticipatory in identifying the drivers and characterising mechanisms of on target resistance.
• Source: Journal of Translational Medicine
• Relevance: “Our findings comprehensively define the clinical and molecular features of PTMC [papillary thyroid microcarcinoma] and may inspire new therapeutic hypotheses.”
• In this novel study, Chinese researchers profiled the first and largest Papillary Thyroid Microcarcinoma Exome and Transcriptome Atlas (PTMETA). They elucidated transcriptomic and genomic features that could affect the therapeutic options available to cancer patients.
• “Surprisingly, integrated analyses of multi-omic data revealed genomic and transcriptomic features of PTMC and identified a unique subgroup with distinct biology and clinical behavior, which in turn may provide a way for individualized intervention,” the authors wrote. “In addition to the presence of BRAF mutations and RET fusions in the TCGA cohort, we also discovered a new molecular signature named PTMC-inflammatory that implies a potential response to immune intervention, which is enriched with AFP mutations, [email protected] fusions, elevated immune-related genes, positive peroxidase antibody, and positive thyroglobulin antibody.”
• The researchers divided PTMC patients into 2 subtypes based on clinicopathological features, gene expressions, genomic alterations, immunotherapeutic responses, and immune microenvironment patterns. They also proposed a molecular prediction model for individualized integrative assessment.
• Their findings shed light on the molecular signatures in PTMC, as well as new perspectives on the molecular mechanism for future research and relevant immunotherapy in PTMC.
• One limitation of the current study is the paucity of treatment and survival data because of short follow-up duration. Consequently, it was hard to elucidate the true value of biomarkers.